Loading
A personalised blood test tracking 50 of each patient's tumour mutations found leftover lung cancer after surgery months before scans did.
PROPHET deep-sequences 50 patient-specific variants to detect residual disease, with a limit of detection of 0.004 per cent. Applied with fixed-panel assays to 760 plasma samples from 181 prospectively enrolled patients with early-stage non-small cell lung cancer, it had higher sensitivity at baseline (45 per cent), outperformed fixed panels for prognosis and gave a median lead time of 299 days to radiologically confirmed recurrence. Non-canonical personalised variants made up 98.2 per cent of those tracked, with prognostic effects similar to canonical ones, and a proposed tumour-node-metastasis-blood classification outperformed TNM staging at the adjuvant decision point.
Personalised panels outperform fixed gene panels after lung cancer surgery, at limits in the tens of parts per million.
Shares brPROPHET, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares brPROPHET, Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/